Vascular endothelial growth factor in systemic lupus erythematosus: relationship to disease activity, systemic organ manifestation, and nailfold capillaroscopic abnormalities by Kuryliszyn-Moskal, Anna et al.
Arch. Immunol. Ther. Exp., 2007, 55, 179–185 DOI  10.1007/s00005-007-0017-7
PL ISSN 0004-069X
Vascular endothelial growth factor 
in systemic lupus erythematosus: relationship 
to disease activity, systemic organ manifestation, 
and nailfold capillaroscopic abnormalities
Anna Kuryliszyn−Moskal, Piotr Adrian Klimiuk, Stanisław Sierakowski 
and Mariusz Ciołkiewicz
Department of Rheumatology and Internal Diseases, Medical University of Bia³ystok, Bia³ystok, Poland
Received: 2006.10.18, Accepted: 2006.12.28, Published online first: 2007.06.08
Abstract 
Introduction: The aim of the study was to evaluate whether vascular endothelial growth factor (VEGF) serum level is associ-
ated with systemic organ involvement, microvascular changes as determined by nailfold capillaroscopy, and disease activity
of systemic lupus erythematosus (SLE). 
Materials and Methods: Serum levels of VEGF were determined by an enzyme-linked immunosorbent assay in 47 SLE
patients and in 30 healthy controls. Nailfold capillaroscopy was performed in all patients and healthy subjects.
Results: Morphological changes were observed by nailfold capillaroscopy in 45 of 47 (95.7%) SLE patients. Mild capillary
changes were found in 16 (34%), moderate in 21 (44.7%), and severe in 8 (17%) SLE patients. All patients with systemic
organ involvement showed severe or moderate changes in nailfold capillaroscopy. In comparison with the control group,
a higher serum concentration of VEGF in SLE patients was demonstrated (p<0.05). Furthermore, significant differences in
VEGF serum concentration between SLE patients with systemic involvement and controls were found (p<0.01).
Comparison between patients with active and inactive SLE according to SLEDAI score showed a significantly higher con-
centration of VEGF in the sera of patients with active SLE (p<0.01). The SLE patients with severe and moderate changes
in nailfold capillaroscopy showed significantly higher VEGF serum levels than SLE patients with mild changes (p<0.05) or
healthy controls (p<0.01). Moreover, the VEGF serum level correlated significantly with ESR (r=0.580, p<0.0001) and
CRP (r=0.512, p<0.005). 
Conclusions: Our data suggest that VEGF serum level may be a useful marker of disease activity and internal organ involve-
ment in SLE patients. Abnormalities in nailfold capillaroscopy may reflect the extent of microvascular involvement and are
associated with systemic manifestation in SLE. 
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ORIGINAL ARTICLE
INTRODUCTION
Systemic lupus erythematosus (SLE) is a progressive
autoimmune disease with a wide range of clinical and
immunological abnormalities. The clinical expression of
SLE is the consequence of its complex immunopatholo-
gy, involving the production of autoantibodies and
immune complex vasculitis with endothelial cell damage
[1]. The vascular endothelial injury associated with
chronic systemic inflammation leads to blood vessel
destruction and serious internal organ dysfunction [5,
16]. Therefore, early detection of vascular involvement
plays an essential role in the diagnostic procedure of
connective tissue diseases (CTDs). Nailfold capillary microscopy has been used as
a non-invasive technique for investigating microvascular
involvement in rheumatic diseases [6, 8, 9, 10]. In our
previous study, morphological changes in nailfold capil-
laroscopy in rheumatoid arthritis (RA) and CTD
patients have been observed [17, 18]. In SLE patients,
a variable prevalence of capillary abnormalities has
been reported [3, 20]. Moreover, the nailfold capillaro-
scopic changes seem to be related to the disease activity
score and the presence of specific autoantibodies [25]. 
The process of new microvessel formation, known as
angiogenesis, plays an essential role in the tissue remod-
eling that occurs in chronic inflammatory rheumatic dis-
eases [15, 27, 28]. Vascular endothelial growth factor
(VEGF), a key modulator of angiogenesis, endothelial
cell proliferation and migration, chemotaxis, and capil-
lary hyperpermeability, is upregulated in a number of
physiological and pathological conditions associated
with hypoperfusion and/or hypoxia [7, 23]. Elevated lev-
els of VEGF have been reported in the serum of
patients with RA, polymyositis/dermatomyositis, and
active SLE compared with healthy individuals [13].
Furthermore, it has been reported that high VEGF lev-
els may be associated with the disease activity of RA [12,
21] and SLE [26]. In our previous studies we demon-
strated significantly elevated serum levels of VEGF in
RA patients with distinct variants of rheumatoid synovi-
tis [14] and in the sera of patients with systemic sclerosis
(SSc) [19] compared with healthy controls. Moreover,
SSc patients with internal organ involvement showed
significantly higher levels of VEGF compared with
those without any evidence of systemic manifestations
[19].
Based on findings suggesting an important role of
endothelial activation in the pathogenesis of some extra-
articular manifestations in rheumatic diseases, we eval-
uated whether the VEGF serum level is associated with
systemic organ involvement, microvascular changes as
seen in nailfold capillaroscopy, and disease activity of
SLE.
MATERIALS AND METHODS 
Patients
Forty-seven patients (44 women and 3 men, mean
age: 41.3±13.8 years) who fulfilled the updated 1982
American College of Rheumatology (ACR) revised cri-
teria for SLE [29] were included in the study, giving
their informed consent. The mean duration of the dis-
ease was 8.1±7.8 years. All patients were evaluated by
extensive clinical and laboratory studies. Physical exam-
ination was performed on the day of blood collection.
Global disease activity was assessed using the Systemic
Lupus Erythematosus Disease Activity Index
(SLEDAI) [2]. The maximum score in this system is 105
points. In the present study, the number of points
ranged from 3 to 22 and we considered a score
<12 points as inactive disease (28 patients) and a score
≥12 points as active disease (19 patients). 
All SLE patients were classified into two groups:
those with internal organ involvement (26 cases) and 21
persons without any evidence of systemic organ mani-
festations in the course of SLE. The group of 26 cases
with internal organ manifestations included 12 patients
with renal involvement (lupus nephritis, proven histo-
logically), 3 patients with lung fibrosis on high-resolu-
tion computed tomography (HRCT) examination, 5
patients with cardiovascular manifestations, 9 patients
with central nervous system manifestations (in the form
of cognitive dysfunction, severe anxiety, and altered
mental function with impaired orientation), and 7
patients with severe vasculitis (ulceration, infarction,
gangrene). In 12 patients, cutaneous vasculitis was
observed. Table 1 shows the characteristics of the
patient groups.
Twenty-one patients were treated with prednisolone
at a low dosage (≤10 mg/day), 26 patients were receiving
higher doses of steroids (>10 mg/day), 21 patients
hydroxychloroquine, and 6 patients immunosuppressive
agents (cyclophosphamide). Higher doses of steroids
and immunosuppressive drugs were not used during the
two months prior to blood examination. 
Control sera were obtained from 30 healthy subjects
matched for sex and age. 
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Table 1. Main clinical and laboratory features of SLE
patients (mean ±SD)
Characteristics Number of patients Percent
Sex (M/F) 3/44
Age (years; mean ±SD) 40.8±13.6 
(range: 20–71)
Disease duration  8.1±7.8
(years; mean ±SD) (range: 0.5–29)
SLEDAI (mean ±SD) 11.2±4.5
Active/inactive 19/28 40.4/59.6
Fever 12 25.5
Cutaneous involvement 24 51.1
Arthritis 25 53.2
Renal involvement 12 25.5
Cardiac involvement 5 10.6
Neurological involvement 9 19.1
Anemia (hemoglobin <12 g/dl) 17 36.2
Leukopenia 11 23.4
(white blood cells <3.5×109/l)
Thrombocytopenia 8 17.0
(platelets <150×109/l)
ESR (mm/h; >20 mm/h) 41 87.2
CRP (>5.0 mg/l) 13 27.7
ANA positive 38 80.9
Anticardiolipin antibody 8 17.0
Treatment: 
low-dose steroids 21 44.6
high-dose steroids 26 55.3
hydroxychloroquine 21 44.6
immunosuppressive agents 6 12.8The study protocol was approved by the local ethics
committee and the patients’ written consent was
obtained. 
Clinical and laboratory analysis 
Clinical, capillaroscopic, and laboratory data record-
ed at the time of serum collection included pulmonary
and renal function tests, renal sonography as well as ery-
throcyte sedimentation rate (ESR), C-reactive protein
(CRP) concentration measured by a radial immunodif-
fusion kit (Nanorid, The Binding Site Ltd., Birmingham,
UK), hemoglobin, platelet counts, urine analysis, serum
creatinine, and urinary protein excretion.
Organ system involvement was defined as: lung
(bibasilar pulmonary fibrosis on HRCT), heart involve-
ment (pericarditis or congestive heart failure on
echocardiography), and kidney (renal function tests and
sonography). Renal biopsy was done if patients fulfilled
the ACR criteria for renal involvement, i.e. persistent
proteinuria >0.5 g/24 h or cellular casts in the absence
of infection [29]. In patients with central nervous system
manifestations such as psychosis, organic brain syn-
drome, lupus headache or cerebrovascular incident,
computed tomography was performed. 
Nailfold capillaroscopy
Nailfold capillaroscopy was performed in all patients
and healthy subjects using a stereomicroscope SZ 4045
(Olympus, Germany) by one investigator with 16 years
of experience in performing nailfold capillaroscopy.
A fiber-optic light source and filter provided cold illu-
mination. Each patient was acclimatized for 20 min at
a room temperature of 20–24°C prior to the examina-
tion. 
The nailfolds of all fingers except the thumbs and
fingers affected by recent local trauma were examined
in each patient. To obtain the best visibility of the
microvascular network, a drop of immersion oil was
placed on the nailfold bed. Only the capillaries in the
distal row of the nailfold were analyzed. The intensity of
the morphological changes was evaluated on the basis of
a semiquantitative method which included the parame-
ters: loop density, capillary length variability (shorter or
longer capillaries), percentage of loops with architectur-
al derangement such as tortuous, meandering, enlarged,
ramified, or bushy capillaries, irregular distribution of
the capillary array, and the presence of extravasations
into the perivascular tissue. The intensity of capillaro-
scopic changes was expressed according to a previous
classification [18] and ranged from 0 to 3, where a score
of 0 indicated no changes or less than 25% morphologi-
cally changed capillaries without perivascular changes,
one were mild (25–50% morphologically changed capil-
laries without perivascular changes), two moderate
(50–75% morphologically changed loops with dimin-
ished loop density, increased visibility of the sub-papil-
lary venular plexus, and without extravasations), and
three were severe changes (more than 75% morpholog-
ically changed loops with the extended architectural
derangement of the microvascular network, heteroge-
neous features of angiogenesis, extravasations into the
perivascular tissue, and extensive visible venous plexus).
The mean score for each subject was obtained from
analysis of all the fingers.
Serum specimen preparation
Blood samples were clotted for 30 min and then cen-
trifuged for 10 min at 1000×g. Serum aliquots were
frozen at –80°C immediately after collection. 
Laboratory studies 
The screening for the presence of autoantibodies to
nuclear antigens (ANAs) was performed by indirect
immunofluorescence microscopy on a commercial
human Hep-2 cell substrate (Viro-Immun Labor
Diagnostica GmbH, Germany). Serial dilutions of the
sera were tested and ANA titer ³1:80 was considered to
be positive. Levels of IgG and IgM anticardiolipin anti-
bodies (ACA) were measured using commercial ELISA
kits (Pharmacia Diagnostics AB GmbH Freiburg,
Germany). The serum concentrations of VEGF were
assessed by an ELISA kit from R&D Systems,
Wiesbaden-Nordenstadt, Germany. Assays were carried
out according to the manufacturers’ instructions. 
Statistical analysis
Data were analyzed by the Mann-Whitney U-test.
The probability of differences in frequency distributions
was determined by chi-square test or Fisher’s exact test.
Data were correlated by Spearman’s rank order test.
p values lower than 0.05 were considered statistically
significant. 
RESULTS
The characteristics of SLE patients with and without
systemic organ involvement are shown in Table 2. No
significant differences in age, duration of disease,
SLEDAI score, ESR levels, the incidence of cutaneous
involvement, ANA positivity, and the presence of ACA
between the two groups of SLE patients with and with-
out systemic involvement were seen. The score of capil-
laroscopic changes were significantly higher in patients
with systemic manifestation of the disease (p<0.001).
Morphological changes in nailfold capillaroscopy
were observed in 45 of 47 (95.7%) SLE patients. Mild
capillaroscopic changes were found in 16 (34%), mod-
erate in 21 (44.7%), and severe in 8 (17%) SLE patients.
All patients with organ systemic involvement showed
severe or moderate changes in nailfold capillaroscopy,
whereby 7 out of 26 (26.9%) had severe changes, i.e.
extended architectural derangement with heteroge-
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perivascular tissue, and 19 out of 26 (73.1%) had mod-
erate capillary abnormalities without signs of angiogen-
esis and microhemorrhages. In the group without organ
systemic manifestation, only one patient (4.8%) showed
severe vascular changes, two patients (9.5%) moderate,
16 (76.2%) mild capillaroscopic abnormalities, and two
patients (9.5%) had no pathological changes in nailfold
capillaroscopy. 
The capillaroscopic feature in the control group
showed hairpin capillaries in a parallel arrangement.
Isolated tortuous capillary loops and meandering, elon-
gated capillaries were found in 5 persons (16.6%) of the
healthy controls.
Serum levels of VEGF were determined in 47 SLE
patients, including 26 patients with systemic involve-
ment, 21 cases without internal organ manifestations,
and in 30 healthy subjects (Fig. 1). The SLE patients had
significantly elevated serum concentrations of VEGF
compared with the age-matched healthy controls
(p<0.05). Although the mean serum level of VEGF was
higher in SLE patients with systemic involvement than
in cases without organ manifestation and in the control
group, a significant difference only between SLE
patients with systemic involvement and controls could
be shown (p<0.01).
Comparison between the SLE groups with active
and inactive disease according to SLEDAI score showed
a significantly higher concentration of VEGF in the sera
of patients with active SLE (p<0.01). Also, the mean
serum level of VEGF was significantly higher in patients
with active SLE than in the control group (p<0.001).
However, VEGF concentrations did not differ signifi-
cantly between the patients with inactive SLE and
healthy controls (Fig. 2). Moreover, VEGF serum level
correlated significantly with ESR (r=0.580, p<0.0001)
and CRP (r=0.512, p<0.005; data not shown). 
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Table 2. Main clinical and laboratory differences in SLE patients with and without systemic organ involvement
Characteristics SLE together
SLE patients SLE patients
p without systemic with systemic
involvement (n=21) involvement (n=26)
Sex (M/F) 3/44 3/18 0/26
Age (years; mean ±SD) 40.8±13.6 44.2±14.3 38.0±12.5 NS
Disease duration (years; mean ±SD) 8.1±7.8 6.3±6.2 9.5±8.7 NS
SLEDAI (mean ±SD) 11.2±4.5 9.8±4.0 12.3±4.7 NS
ESR (mm/h; mean ±SD) 34.2±24.9 33.8±26.3 34.6±24.3 NS
Nailfold capillaroscopy (score; mean ±SD) 1.8±0.9 1.1±0.7 2.3±0.5 <0.001
Cutaneous involvement (n/%) 24/51.1 8/38.1 16/61.5 NS
Raynaud’s phenomenon (n/%) 4/8.5 2/9.5 2/7.7 NS
CRP (>5.0 mg/l; n/%) 13/27.7 7/33.3 6/23.1 NS
ANA positive (n/%) 38/80.9 15/71.4 23/88.5 NS
Anticardiolipin antibody (n/%) 8/17.0 3/14.3 5/19.2 NS
Treatment: 
low-dose steroids (n/%) 21/44.7 11/52.4 10/38.5 NS
high-dose steroids (n/%) 26/55.3 10/47.6 16/61.5 NS
hydroxychloroquine (n/%) 21/44.7 11/52.4 10/38.5 NS
immunosuppressive agents (n/%) 6/12.8 2/9.5 4/15.4 NS
NS – not significant.
Fig. 1. Serum concentrations of VEGF in SLE patients with and
without internal organ involvement. Box plots represent median
(line), 25th and 75th percentiles (box), and whiskers indicating the
10th and 90th percentiles. NS – not significant. 
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Fig. 2. Serum concentration of VEGF in patients with active and
inactive SLE. Data are presented as described in Fig. 1. 
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nailfold capillaroscopy (score >1) showed significantly
higher VEGF serum levels than SLE patients with mild
changes (p<0.05) and healthy controls (p<0.01; Fig 3).
Typical abnormalities representative of patients with
capillaroscopic scores 0–1 and scores 2–3 are shown in
Fig. 4A and B, respectively. 
DISCUSSION 
Recently, many studies have concentrated on the
role of angiogenesis and microvascular endothelial
injury in the pathogenesis of systemic organ involve-
ment in rheumatic diseases, such as SLE [4]. One of the
key players in the process of new vessel formation is
VEGF [7, 23]. Several studies have reported elevated
levels of VEGF in the plasma [22] and serum [26] of
SLE patients. Moreover, a relationship between VEGF
serum levels and SLE activity score was observed [26].
Other investigators reported that VEGF is increased in
plasma from patients with lupus nephritis and a moder-
ate degree of renal failure [22]. Since in our previous
study a relationship between capillaroscopic abnormali-
ties and extra-articular manifestations of RA and CTD
patients was observed [18], we investigated whether the
VEGF serum level is associated with systemic organ
involvement, microvascular capillaroscopic changes,
and disease activity in SLE patients.
In our previous study we demonstrated that sys-
temic lesions in the course of RA and CTD are accom-
panied by microvascular injury observable under capil-
lary microscopy [18]. Growing evidence points to the
diagnostic value of nailfold capillaroscopy in rheumatic
diseases [6, 8, 9, 10]. However, little data exist on the
relationship between immunological alterations, inter-
nal organ involvement, and capillaroscopic abnorma-
lities. 
In the present study, all SLE patients with internal
organ manifestations showed severe (26.9%) or moder-
ate (73.1%) pathological changes under nailfold capil-
laroscopy. Mild changes in capillaroscopy in patients
with systemic involvement were not observed. In the
group without systemic manifestations, only one patient
(4.8%) showed severe and two patients (9.5%) moder-
ate vascular abnormalities. In four patients with
Raynaud’s phenomenon, the so-called capillarosco-
pic SD-pattern (scleroderma disease pattern) was
observed.
Although capillaroscopic changes are not specific to
SLE, we demonstrated more severe morphological
abnormalities, such as extended architectural derange-
ment with heterogeneous features of angiogenesis and
microhemorrhages in patients with higher disease activ-
ity. Only one patient with inactive SLE had severe vas-
cular changes. This may confirm the findings of other
authors [25] that microvascular changes may be related
to a more severe disease state. Moreover, it has been
demonstrated that severe capillaroscopic abnormalities
correlated with the presence of the main autoantibodies
[24, 25] and pulmonary function impairment [11]. In our
study, three patients with pulmonary involvement
showed severe vascular changes. 
In the present study, the VEGF serum concentra-
tion was significantly higher in all SLE patients com-
pared with healthy controls. Moreover, VEGF reached
the highest serum levels in patients with organ involve-
ment, although no significant differences between the
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Fig. 3. Serum concentration of VEGF in patients according to the
score of capillaroscopic changes (described in Materials and
Methods). Data are shown as presented in Fig. 1.
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Fig. 4. Typical abnormalities representative of patients with capil-
laroscopic scores 0–1 and scores 2–3 are shown in Fig. 4A and B,
respectively. Details described in the text. 
A
BSLE groups with and without systemic manifestations
were found. Other investigators reported that patients
with renal failure had significantly elevated plasma lev-
els and overexpression of VEGF in renal tissue com-
pared with SLE patients with normal renal function
[22]. It is postulated that this factor might be involved
in glomerular endothelial repair [22]. In our study 12
out of 26 (46.2%) SLE cases with internal organ mani-
festation had renal involvement. No significant differ-
ences between SLE patients without systemic involve-
ment and healthy controls may confirm that VEGF may
be a useful marker of systemic involvement in SLE
patients.
It has been postulated that inflammation may have
an influence on endothelial function in rheumatic dis-
eases [30]. The results of this study confirm that in
patients with active SLE the serum concentration of
VEGF is significantly higher than in healthy controls or
patients with inactive disease [26]. It is postulated that
the imbalance between VEGF and its soluble receptors
may be important in the pathogenesis of SLE [26].
Moreover, we demonstrated correlation of VEGF with
such clinical and laboratory markers of disease activity
as ESR and CRP. In our previous study, serum concen-
tration of VEGF was found to correlate with ESR and
CRP in RA patients [14]. 
In the present study we demonstrated significantly
higher serum levels of VEGF in SLE patients with
severe and moderate abnormalities in capillaroscopy
compared with patients with mild changes. Among the
29 patients with severe or moderate changes in nailfold
capillaroscopy, 15 cases (51.7%) were active according
to the SLEDAI score and in the group with mild vascu-
lar changes, 4 patients out of 18 (22.2%) had active dis-
ease. Therefore, further studies are needed to confirm
whether the serum level of VEGF reflects the extent of
microvascular damage in SLE patients.
Although the titer of anti-dsDNA antibodies were
higher in the group with systemic involvement com-
pared with those without this complication, no correla-
tion between the autoantibodies and VEGF serum lev-
els was found (data not shown). In addition, serum con-
centrations of VEGF did not differ significantly
between the patients with and without immunosuppres-
sive treatment (data not shown). 
Our findings point to an important role of VEGF in
the pathogenesis of systemic organ involvement in SLE
patients. Abnormalities in nailfold capillaroscopy may
reflect the extent of microvascular involvement in SLE.
Nailfold capillaroscopy can be useful in the diagnostic
procedure of the disease and lead to more effective
strategies in the treatment of systemic organ dysfunction
in SLE.
In conclusion, the serum level of VEGF may be
a useful marker of disease activity and internal organ
involvement in SLE patients. Nailfold capillaroscopy
abnormalities may reflect the extent of microvascular
involvement and are associated with systemic organ
manifestations in SLE.
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